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Curcumin Mediates Both Dilation and Constriction of
Peripheral Arterioles via Adrenergic Receptors
Anthony M. Dewar1, Richard A. Clark1,2, Adam J. Singer3 and Mary D. Frame1,4
Curcumin has wound healing attributes mediated through a plethora of biological activities that in general are
not ascribed to specific receptors. Recently, we have demonstrated that intravenous administration of curcumin
limits burn injury progression in a rat model. As decreased microvascular perfusion is a central element of burn
injury progression, we hypothesized that curcumin may induce vasodilation in peripheral arterioles, to improve
perfusion. Using mucosal microcirculation as an in situ assay, cheek pouch tissue was exteriorized in
anesthetized (phentobarbital 70mgkg1 intraperitoneal) male hamsters (N¼ 60) to observe the terminal feed
arterioles (B8 mm diameter) and the immediately upstream arcade arterioles (B20 mm). Curcumin
(1012–104mol l1) was applied dose-wise (micropipette, 60 seconds). Subnanomolar curcumin dilated, whereas
micromolar doses constricted, the arterioles. For the terminal arteriole: vasodilation logEC50 10.3±0.2, peak
dilation þ 39±1%; vasconstriction logEC50 8.0±0.4, peak constriction 14±2%. Simultaneous atropine
(muscarinic antagonist) or PD142893 (endothelin antagonist) had no effect. Propranolol (b-adrenergic receptor
(b-Ad) antagonist) enhanced constriction by removing the vasodilation response to curcumin. Phentolamine
(a-adrenergic receptor (a-Ad) antagonist) enhanced dilation to curcumin by removing the vasoconstriction
response. Thus, the curcumin vasomotor activity on microcirculation was a-Ad and b-Ad receptor-dependent
and its net vasoactive effect was concentration- and time-dependent.
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INTRODUCTION
Curcuma longa (turmeric), an herb belonging to the ginger
family, has wound healing properties attributable to a
plethora of specific biologic activities that have not for the
most part been ascribed to a known receptor (Aggarwal and
Sung, 2009). Recently, we have shown that administration of
curcumin to rats before (gastric gavage) or 1 hour after
(intravenous) hot comb burns will limit injury progression
(Singer et al., 2007, 2011) in a manner unrelated to its
antioxidant properties (Singer et al., 2011). Alternatively,
blood vessel occlusion by red blood cell plugging and
thrombosis formation is found in the ischemic tissue
surrounding a burn (Moritz, 1947; Regas and Ehrlich, 1992;
Vo et al., 1998) and may be why tissue necrosis extends from
the primary burn site. As curcumin is vasoactive in large
arteries from some tissues and species (Sasaki et al., 2003;
Gilani et al., 2005; Xu et al., 2007; Ahn et al., 2009), we
wondered whether some of the beneficial effect of curcumin
was related to a vasomotor effect on the microvasculature.
Few studies have shown that curcumin is vasoactive; no
previous report has investigated curcumin’s action on the
microcirculation. Studies in macrovessels typically tested
micromolar levels of various curcuminoid preparations and
found a decrease in tension development for artery rings from
porcine coronary arteries, rat aorta, and rabbit basilar arteries
(Sasaki et al., 2003; Xu et al., 2007; Ahn et al., 2009), but not
rabbit aorta (Gilani et al., 2005); decreased tension is
interpreted as dilation. From the limited literature, the
mechanism by which curcumin decreases tension appears
to be at most half nitric oxide (NO) mediated (half attributed
to b-adrenergic receptor (b-Ad), Xu et al., 2007), yet the
vasoactivity appears to widely differ by tissue and species, or
perhaps by curcuminoid preparation or extraction procedure.
An important consideration from the cell culture literature is
the well-documented cytotoxicity of curcumin, beginning at
concentrations of 105mol l1 (Foresti et al., 2005; Gilani
et al., 2005; Kunwar et al., 2008). Thus, any response, or lack
thereof, to curcumin in the micromolar range should be
interpreted carefully.
In this study, we define the vasoactive response to
curcumin in peripheral mucosal arterioles using the hamster
cheek pouch in situ assay. The buccal mucosa of the hamster
has a two-dimensional microcirculation, which greatly
facilitates direct microscopic examination of vasoactive
responses. In humans, both the buccal mucosa and cutaneous
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microcirculation consist of three-dimensional capillary
loops, which arise from deeper feeding arterioles (Braverman,
1997; Scardina et al., 2009). However, the diverse tissues
display a similar vasoactive response capability (Gyorfi et al.,
1992; Oaklander and Siegel, 2005) to what is found for the
hamster cheek pouch (Frame and Mabanta, 2007; Frame
et al., 2007; Georgi et al., 2010), likely due to a similar
vascular receptor distribution that includes adrenergic,
muscarinic, and endothelin (ET) receptors (Hardman and
Limbird, 2001). Thus, the hamster cheek pouch microcircu-
lation was used as an in situ assay model system to facilitate
direct investigation of possible curcumin vasoactivity on
the microcirculation and, if any, of the receptor system
by which it acts.
In this study, we hypothesized that ethanol extracted
curcumin I (99% purity, Singer et al., 2007) would induce a
robust vasodilation in peripheral arterioles. In the hamster
cheek pouch, we found that small arterioles do dilate to
subnanomolar concentrations of curcumin. We also report
that higher concentrations induce a robust constriction
unrelated to vasoactivity of the vehicle ethanol. Both
responses are recoverable. Further, the constrictor response
is mediated by a-adrenergic (a-Ad) receptors, and the dilatory
response is entirely mediated by b-Ad receptors and requires
cyclic guanosine monophosphate (cGMP), yet, not all
dilation appears to require NO formation.
RESULTS
Over the 60 seconds exposure time, low nanomolar and
picomolar concentrations of curcumin induced a sustained
dilation. At higher concentrations, initial vasodilation at
20 seconds was followed by vasoconstriction at 60 seconds.
One experiment is shown in Figure 1 to illustrate the time and
concentration dependence of this response. (Illustrative
examples of control, dilated, and constricted arterioles are
shown in Figure 1). Thus, we examined two separate
concentration–response relationships: the early response at
20 seconds of exposure and the late response at 60 seconds of
exposure (Figure 2a). Corresponding effective concentration
at half-maximal response and maximal values are given in
Supplementary Table S1 online. Peak dilation was signifi-
cantly greater for terminal arterioles versus arcade arterioles.
Two important controls were performed to determine
whether the biphasic nature of the vasomotor response to
curcumin was attributable to vehicle (ethanol) or to a
cytotoxic effect of curcumin over the course of the experi-
ments. Although vehicle (ethanol) alone caused significant
constriction at 0.1 and 1% (Figure 2b), only the highest
concentration of ethanol (1%) yielded a constriction that
could not be distinguished from constriction to curcumin.
Furthermore, the initial vasodilation response cannot be
explained as a response to vehicle, and therefore must be a
response to curcumin itself. To determine whether vasocon-
striction responses to curcumin were attributable to a
cytotoxic effect, we demonstrated that both constrictor and
dilatory (cGMP and cAMP mediated) responses were un-
changed before versus after repeated exposure to curcumin
(Supplementary Table S2 online). Thus, curcumin stimulated
a recoverable dose- and time-dependent dilation/constriction
response in hamster cheek pouch arterioles.
Adrenergic blockade suppressed the response to curcu-
min. Blockade was confirmed (Supplementary Table S3
online). Figure 3a shows that the dilation response to
curcumin in the terminal arteriole was abolished by
propranolol and the constriction response abolished
by phentolamine. Propranolol and phentolamine applied
together blocked all response to curcumin (Figure 3b). We
eliminated the possibility that curcumin was initiating part or
all of these vasoactive effects through stimulation of the
sympathetic nerves causing norepinephrine release by show-
ing that, although 6-hydroxy dopamine did significantly
decrease baseline diameters (terminal arteriole, from
9.4±0.8 to 11.2±0.6 mm; arcade arteriole, from 19±3 to
29±4 mm), it did not remove the response to curcumin
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Figure 1. Arteriolar location and time dependence of diameter changes.
Representative images of the arcade arteriole–terminal arteriole junction with
micropipette placement for curcumin administration (schematic, b) in the
basal control state (a), constricted with phenylephrine (c), and dilated with
adenosine (d). Dashed lines in panel b indicate typical locations for diameter
measurements. White arrow points to a bulge, which is a vascular smooth
muscle cell in cross-section; especially in panel c the cells are seen as a
‘‘string of pearls’’ along the vascular wall. With dilation (d) the cells flatten
and are not apparent. (e) Time course of the diameter change in response to
continuous curcumin application (micropipette) in one terminal arteriole.
Low-dose curcumin induced a sustained vasodilation, peaking by 20 seconds.
Higher dose curcumin initiated dilation, peaking by 20 seconds, followed by
a secondary constriction, peaking by 60 seconds. Data for concentration
response analysis were thus taken at both the early (20 seconds) and late
(60 seconds) time periods. Scale bar in a–d is 20 microns.
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(Supplementary Table S1 online). Thus, the response to
curcumin was prevented with total adrenergic blockade, and
not by blocking sympathetic nerves, suggesting a direct
action on the vascular wall by curcumin.
Atropine (muscarinic antagonist) or PD142893 (ET an-
tagonist) each diminished the maximal dilation and enhanced
the maximal constriction to curcumin (Supplementary Table
S1 online), yet had no effect on baseline diameters. Blockade
was confirmed (Supplementary Table S3 online). Although
muscarinic or ET receptor-mediated actions may be involved
in modulating the response to curcumin, they are not
required.
The b-Ad receptors may be present on endothelial cells,
where they induce a NO, cGMP-mediated dilation. Alter-
natively, or in addition, b-Ad receptors may be present on
vascular smooth muscle cells where they induce a cAMP-
mediated dilation (Hardman and Limbird, 2001). The NO
dependence of dilation to curcumin was tested by blocking
endogenous NO formation with No-nitro-L-arginine (LNNA).
With 105 M LNNA, dilation to curcumin was attenuated to
an equivalent extent in both the terminal feed and arcade
arterioles; however, a significant dilation remained at the
1012 to 1010 M curcumin concentrations (Figure 4a). At
higher 104 M LNNA, significant residual dilation remained
for the lower concentrations of curcumin (Figure 4b).
Blockade was confirmed (Supplementary Table S3 online).
These results suggested that dilation was mediated by NO at
least in the nanomolar and micromolar range, but other
mechanism(s) contributed to the microcirculation response in
the picomolar range, perhaps consistent with low concentra-
tions acting through an alternate G-protein system, or the
high concentrations preferably acting directly on the down-
stream kinase elements (Hardman and Limbird, 2001; Sun
et al., 2007).
Next, we blocked cGMP and cAMP directly, using the Rp
isomers, Rp-8-br-cGMPS and Rp-8-br-cAMPS (Figure 5).
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Figure 2. Arteriolar responses to curcumin or vehicle. Concentration–response relationship for curcuminþ vehicle (a) or vehicle alone (b, ethanol) applied to
arcade and terminal feed arterioles (Protocol 1). (a) The early response was obtained at 20 seconds and the late response was obtained at 60 seconds of
continuous exposure to curcumin. The effective concentration at half-maximal response and maximal values are given in Supplementary Table S1 online.
*, Terminal and **, arcade: individual responses differ from baseline, Po0.05. (b) Time course of the response to ethanol alone, showing the percent ethanol
(in the corresponding curcumin solution). Terminal and arcade arterioles are combined. The response at 60 seconds (circled) corresponds to the late time point
in panel a for all ethanol concentrations. *Differs from baseline for 0.1 and 1% ethanol only, Po0.05.
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Figure 3. Propanolol, a b-adrenergic antagonist, inhibited curcumin-induced vasodilation, while phentolamine, an a-adrenergic antagonist inhibited
curcumin-induced vasoconstriction. Shown are the early (20 seconds) and late (60 seconds) diameter changes in response to curcumin in the presence of 105 M
propranolol or 105 M phentolamine separately (a) or together (b) (Protocol 2). Three concentrations of curcumin were tested in panel b: 1010, 108, and
106 M. Responses are shown only for the terminal arteriole in panel a, and for both arcade and terminal feed arterioles in panel b. The effective concentration at
half-maximal response and maximal values for both the terminal arteriole and arcading arteriole are given in Supplementary Table S1 online. *, Phentolamine
and **, propranolol: individual responses differ from baseline, Po0.05.
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Blockade was confirmed (Supplementary Table S3 online).
Blocking cAMP significantly suppressed dilation to curcumin
at 106mol l1 for the arcade, but not terminal arterioles
(Figure 5). Furthermore, in arcade arterioles the constrictor
response to 108mol l1 curcumin was attenuated with
Rp-8-br-cAMPS. Blocking cGMP prevented all dilation to
curcumin in both the terminal and arcade arterioles (Figure 5).
Thus, the dilation to curcumin appears to require cGMP
for both classes of vessels, yet a significant role for
cAMP-mediated dilation is suggested for the larger arcade
arterioles.
DISCUSSION
Here we show that picomolar to low nanomolar concentra-
tions of curcumin I induced a sustained vasodilation in
hamster cheek pouch peripheral arterioles that was depen-
dent on b-Ad receptor activity (Figure 6). Dilation was
consistent with the response to curcumin observed for
coronary arteries (Xu et al., 2007). However, curcumin in
the micromolar range induced sustained microvasculature
constriction that was dependent on a-Ad receptor activity. In
contrast, other studies using large arteries demonstrated that
micromolar concentrations of curcumin induced decrease
tension that was interpreted as vasodilation (Sasaki et al.,
2003; Gilani et al., 2005; Xu et al., 2007; Ahn et al.,
2009). Persistent vasoconstriction in vascular tissue to
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Figure 5. Inhibition of cyclic guanosine monophosphate (cGMP) abolished
curcumin-induced vasodilation. Shown are the early (20 seconds) and late
(60 seconds) diameter changes in response to curcumin in the presence of
105 M Rp isomers to block cGMP (Rp-8-br-cGMPS) or cAMP (Rp-8-br-
cAMPS; Protocol 3). Two concentrations of curcumin were tested: (a) 108 M
and (b) 106 M. Responses are shown from both the terminal arterioles
(a and b) and arcade arterioles (c and d). *Differs from control for the
associated early versus late response.
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Figure 6. Schematic of hypothesized mechanism of vasoaction for purified
curcumin I in the peripheral microcirculation for terminal (nutritive)
arterioles or arcade arterioles that feed them. Curcumin induces
vasoconstriction that requires a-Ad, and vasodilation that requires b-Ad.
EC-dependent dilation occurring through endothelial nitric oxide synthase
(eNOS), nitric oxide (NO), and cyclic guanosine monophosphate (cGMP)
accounts for most of the dilation; we hypothesize that this is linked to the
receptor G-protein subunit Gq and independent of Gi or mitogen-activating
protein kinase (MAPK) activity. VSM-dependent dilation occurring through
cAMP accounts for a smaller portion of the dilation, significant in only the
arcade arterioles; based on the data presented here, we hypothesize that this
is linked to the G-protein subunit Gas. a-Ad, a-adrenoceptor (VSM
constriction); b-Ad, b-adrenoceptor (EC or VSM dilation); EC, endothelial cell;
VSM, vascular smooth muscle cell.
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alcohol-extracted curcumin I is to our knowledge a pre-
viously unreported finding, which cannot be attributed to
transient responses to vehicle alone.
Propranolol blocked all dilation to curcumin. In this tissue,
b2-Ad are present (Koo, 1984), but it was unknown whether
they resided on endothelial and/or vascular smooth muscle
cell types. While a2-Ad can induce dilation in some tissues
and species (Crassous et al., 2009), their role was not
investigated secondarily due to our conclusive findings with
propranolol. We investigated the cell type pharmacologically
with LNNA (to block endothelial-dependent dilation) and
then with Rp isomers. With LNNA, dilation remained
significant for the picomolar concentrations of curcumin,
suggesting that the NO–cGMP pathway was required.
Supporting this possibility, abrogating cGMP formation
directly, prevented significant dilation. We did not investigate
whether curcumin was acting on a kinase downstream of the
b2-Ad receptor (for example, mitogen-activating protein
kinase, extracellular signal-regulated kinases 1/2, and have
not ruled out an inverse agonism effect (Hardman and
Limbird, 2001; Woo et al., 2005; Sun, McGarrigle and
Huang, 2007). Our finding is strikingly different from that of
Xu et al. (2007), who reported that only half of the dilation to
(synthesized) curcumin I in porcine coronary arteries is
blocked with propranolol.
Dilation to curcumin was greater for the terminal arterioles
than the arcade arterioles. This is consistent with findings in
the microvasculature of the rat cremaster, in which the
terminal arterioles exhibited a more robust dilation through
cGMP than did the arcade arterioles (Frame et al., 2002), and
may underlie a fundamental difference in the responses for
these two classes of arterioles. The arcade arterioles were
sensitive to cAMP blockade, suggesting a significant role for
vascular smooth muscle cell b-Ad receptors in mediating the
dilation to curcumin. We speculate therefore that the residual
dilation at low curcumin concentrations with LNNA is
through the vascular smooth muscle b-Ad, the magnitude of
which differs by vessel class in this tissue.
We investigated alternate mechanisms that could
explain a residual dilation with LNNA, and eliminated the
possibility of an indirect process for curcumin-induced
dilation through sympathetic nerve release of norepinephrine
(6-hydroxy dopamine data). Finally, based on the literature,
we do not believe that an alternate mechanism is responsible
for these effects. For example, curcumin has a host of
actions on cellular processes (Aggarwal and Sung, 2009),
including induction of hemeoxygenase-1 that produces
carbon monoxide (CO, Ryter et al., 2005). CO targets
guanylyl cyclase to produce cGMP, causing vasodilation
(Samora et al., 2010). However, the several hour timeline
of curcumin-induced expression of hemeoxygenase-1 does
not fit our vasoactive responses, which were acute and
immediate.
Comparing our study to the paucity of literature examining
vasoactive responses to curcumin, we speculate that three
factors are important to account for differences in response:
the curcuminoid itself; the toxic nature of micromolar
curcumin; and the vessel size and species tested. From the
literature, constriction to curcumin (seen as increased force
development in arterial rings) has only been shown for the
polysaccharide extracted component of crude curcumin
(Sasaki et al., 2003) or for non-vascular tissue (Gilani et al.,
2005). The highly purified curcumin preparation that we used
was solvent extracted followed by high-pressure liquid
chromatography verification of curcumin I (499%; Singer
et al., 2007), and thus constriction in our hands is not due to
other curcuminoids. Previous findings by others using crude,
solvent-extracted curcumin I, or synthesized curcumin I,
indicated decreased tension (interpreted as vasodilation) in
artery rings in the micromolar range, without evidence of
increased tension (vasoconstriction; Sasaki et al., 2003;
Gilani et al., 2005; Xu et al., 2007; Ahn et al., 2009). The
authors’ interpretation of their data was that the continued
decrease tension observed with increasing concentrations of
curcumin was attributable to b-adrenergic receptors, part of
which was prevented by propranolol (Xu et al., 2007).
However, a return to control tension after curcumin removal
was not shown for these studies, and in most cases the total
time of curcumin exposure was not given (Foresti et al.,
2005; Gilani et al., 2005; Kunwar et al., 2008). It is
therefore unknown whether the total change in tension was
an active process in these macrovessels, or whether high
curcumin concentrations were cytotoxic over their incuba-
tion periods. In contrast, we directly observed small arterioles
in situ with brief exposures and verified return to baseline.
Curcumin induced a robust, sustained vasodilation at
picomolar to low nanomolar levels that was completely
recoverable with repeated 60 seconds exposures, as evi-
denced by no change in dilatory and constrictor capability
before versus after curcumin. To our knowledge the
vasoactive response of curcumin in peripheral microvessels
is previously unreported.
In conclusion, in the hamster cheek pouch model,
curcumin is a potent vasodilator in the subnanomolar
concentration range, shifting to constriction in the micro-
molar range. Both responses can be attributed to adrenergic
receptors directly. Upon examination of the molecular
structure of curcumin (Aggarwal and Sung, 2009) and its
close similarity to norepinephrine, and a-Ad or b-Ad agonists
and antagonists (Hardman and Limbird, 2001), our finding
that curcumin functions through these receptors is not
surprising. Expanding our interpretation of these findings to
other microvascular tissue beds, curcumin is capable of
inducing either constriction or dilation, and dilation can be
endothelium-dependent or -independent. The precise
adrenergic receptor distribution in each tissue will determine
vasoactive responses to curcumin.
Importantly, the clinical relevance of this finding is
directly related to our ongoing work that shows the beneficial
effect of nanomolar curcumin in ameliorating thermal burn
progression (Singer et al., 2007, 2011). In specific, curcumin
administered intravenously 1 and 24 hours after thermal
injury reduced burn injury progression (Singer et al., 2011). A
potential mechanism by which this occurs is by dilation of
the blood vessels in the immediate vicinity of the burn, in the
zone of potential ischemia.
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MATERIALS AND METHODS
Animal model
With approval by the State University of New York at Stony Brook’s
Institutional Animal Care and Use Committee, male adult hamsters
(120±12 g, 116±34 days, N¼ 60) were anesthetized with pento-
barbital sodium (70mg kg1 intraperitoneal) and tracheostomized.
The left cheek pouch tissue was exteriorized and dissected for
intravital microscopy observations of terminal arterioles coursing
through loose areolar connective tissue on the adventitial side of the
pouch. The thick keratinocyte layer that is normally open to the
buccal cavity was placed face down on the dissection board and not
directly observed. For additional histological orientation, please
refer to Figure 1 in reference Murray et al. (2010). The control tissue
bath solution was bicarbonate-buffered saline (in mmol l1: 132
NaCl, 4.7 KCl, 2.0 CaCl2, 1.2 MgSO4, and 20 NaHCO3 (equilibrated
with gas containing 5% CO2-95% N2 gas, pH 7.4 at 34 1C, without
proteins added; Frame and Mabanta, 2007; Frame et al., 2007;
Georgi et al., 2010), which was flowed continuously over the tissue
at 5mlmin1. Adenosine (104mol l1) and phenylephrine
(104mol l1) were dripped onto the tissue and used to confirm
dilator and constrictor tone, respectively. Thirty minutes later,
microvascular responses (diameter change) were obtained according
to Protocols 1–3, below.
Arteriolar networks
The hamster cheek pouch is a 400–500 mm thick tissue composed of
repeating terminal arteriolar networks arising from arcading arter-
ioles. One terminal arteriolar network consists of a terminal feed
arteriole providing nutrient flow to 3–5 terminal branches (Frame and
Mabanta, 2007; Frame et al., 2007; Georgi et al., 2010). By
definition the terminal branches only feed capillaries. The cheek
pouch tissue is composed of both a muscular and mucosal region.
The mucosal region is innervated by only sensory nerves, whereas
the muscular region (retractor muscle) is innervated by sensory, motor,
and autonomic nerves (Grasby et al., 1999); here, we examined the
mucosal region only. In this study, curcumin was applied through
micropipette to the entrance to the terminal network as the terminal
arteriole arose from the arcade, thus defining the response to curcumin
for two classes of blood vessels: conduit arcade arterioles and nutritive
terminal arterioles (directly feeding capillaries).
Micropipette drug application
Micropipettes were made (Pipette Puller, Model 740 David Kopf
Instruments Tujunga, CA) with 4–8mm diameter tip openings over a
distance of 100–200 mm. They were backfilled with test agents plus a
flow tracer, 105mol l1 FITC–BSA, and positioned B25mm from
the vessel wall. Controlled delivery of test agents was achieved using
a pressure ejection system (MPPI-2, Applied Scientific Instrumenta-
tion, Eugene, OR), in which the balance pressure was set so that no
FITC dye ejection was visible in the holding position, and the
ejection pressure was the minimum that provided a steady outflow of
FITC (typically 0.2 psi). Owing to the position of the micropipette
relative to the test arteriole and the constantly flowing superfusate,
micropipette contents were washed over the test arteriole and then
immediately removed from the observation site. Using this
technique, the volume ejected in a typical exposure is on the order
of picoliters, and the concentration of test agents at the wall of the
vessel is estimated to be half of the concentration in the pipette
(Georgi et al., 2010). Micropipette drug exposure was preceded by a
30-second baseline, and the test agent was applied for a prescribed
time, as noted for individual protocols.
Protocol 1—locally applied curcumin
Curcumin obtained from Chromadex (Irvine, CA) was previously
tested for purity; this ethanol extraction process followed by
preparative high-pressure liquid chromatography yields curcumin I
(499%) as demonstrated by mass spectroscopy (Singer et al., 2011).
The purified curcumin (102mol l1) was stored at 80 1C in ethanol
until used, and then diluted in control suffusate (1012–104mol l1,
n¼ 7). In each animal, two to three networks were tested (minimum
of 500mm apart), performing the complete concentration–response
at each site. We have previously shown that this distance assures
independent observations in this tissue (Frame and Mabanta, 2007;
Frame et al., 2007; Georgi et al., 2010); with curcumin, likewise,
there was no difference in responses between sites. The highest dose
of curcumin tested (104mol l1) contained 1% ethanol. An ethanol
dose–response was repeated here using 0.0001–1% ethanol,
encompassing the range of 108–104mol l1 curcumin (n¼ 3).
Curcumin, or ethanol alone, was applied for 60 seconds through
micropipette to the junction where the arteriolar terminal feed arose
from the arcade, exposing both vessel segments.
Protocol 2—suffusate applied antagonists
Only one antagonist was tested per animal, and two to three sites
that were more than 500 microns apart were tested per animal.
Phentolamine (a-Ad receptor antagonist, 105mol l1, n¼ 6),
propranolol (b-Ad receptor antagonist, 105mol l1, n¼ 6), atropine
(muscarinic receptor antagonist, 107mol l1, n¼ 7), or LNNA
(LNNA, nitric oxide synthase antagonist 105mol l1, n¼ 5; and
104mol l1, n¼ 7) were added to the flowing control suffusate for
5minutes before and then continuously while Protocol 1 was
performed. In five additional animals, phentolamine and propranolol
were applied together. Blockade was confirmed with phenylephrine
(a-Ad receptor agonist, 105mol l1), isoproterenol (Ad receptor
agonist, 105mol l1), acetylcholine (muscarinic receptor agonist,
104mol l1), and nitroprusside (cGMP-mediated dilation agonist,
104mol l1).
The sympathetic nerve toxin, 6-hydroxy dopamine (103mol l1,
n¼ 5) was applied to a stationary tissue bath. Suffusate flow was
stopped, and bone wax was used to create a pool encircling the
cheek pouch tissue. The neurotoxin was added to the pool for
20minutes. Then, control suffusate flow was returned, and Protocol
1 was performed.
Protocol 3—micropipette applied antagonists
Only one antagonist was tested per animal, and two to three sites
were tested per animal. PD142893 (ET receptor A and B antagonist,
105mol l1, n¼ 4) was applied to the observation site through
micropipette for 5minutes before and then continuously during
curcumin exposure. Curcumin (1012–104mol l1) was applied in
increasing concentrations, as per Protocol 1. Rp-8Br-cGMPS (cGMP
antagonist, 104mol l1) or Rp-8Br-cAMPS (cAMP antagonist,
104mol l1), separately and together at separate sites within the
same animal (n¼ 5), was applied to the observation site through
micropipette for 5minutes before and then continuously during
curcumin exposure to only 108 or 106mol l1 curcumin.
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Blockade was confirmed with nitroprusside (cGMP-mediated
dilation agonist, 104mol l1) and adenosine (cAMP-mediated
dilation agonist, 104mol l1).
Microscopy and videorecording
The vasculature was observed using a modified Nikon (Tokyo, Japan)
upright microscope with infinity optics. Data were obtained using a
Nikon  50 LWD objective (NA 0.45) imaged with a Gen/Sys
intensifier and charge coupled device 72s (Dage MTI, Indianapolis, IN)
camera, and recorded with a Panasonic AG-7350 SVHS (Secaucus, NJ)
videorecorder. Diameter was measured off-line using a videocaliper
system (FOR-A, Fort Lee, NJ) calibrated with a scale micrometer.
Statistical analysis
Diameter changes were calculated as the fractional change from
baseline, ((baseline–peak)/baseline). The fractional change is re-
ported to facilitate comparison of two sizes of arterioles. The level of
dilatory and constrictor tone was similar for each class of arteriole.
Concentration–response relationships were analyzed by fitting a
sigmoid-shaped curve to the mean values and obtaining the effective
concentration at half-maximal response and maximal values (Origin
Laboratories Software (Northampton, MA), weighted by standard
deviations). Comparisons were made between treatments using
unpaired t-tests; when comparisons involved multiple sequential
treatments (for example, doses), analysis of variance for repeated
measures was used. All experimental design employed a
b-probability function of 0.6, a priori, and a statistical significance,
a-probability function of 0.05, post hoc (Snedecor and Cochran,
1974).
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